SAB Biotherapeutics Inc. Common Stock (SABS)

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

86

Website

www.sab.bio/

Fundamentals

1-day range

$3.79$3.95

Market cap

$289.80M

P/E (trailing)

26.94

P/E (forward)

-3.97

EPS (trailing)

$-1.42

Dividend yield

—

Beta

0.61

Avg. volume

681.7K

Forecasts

11 analyst ratings

SAB Biotherapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $289.80MP/E 26.94
  $1.85$5.15
• LCTX

  Lineage Cell Therapeutics Inc. Common Stock

  $1.11

  ▼ 4.31%
  Market cap $276.72MP/E —
  $1$2.09
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $273.38MP/E —
  $2.26$10.4
• EDIT

  Editas Medicine Inc. Common Stock

  $3.15

  ▼ 4.55%
  Market cap $259.45MP/E —
  $1.66$4.54
• SRZN

  Surrozen Inc. Common Stock

  $22.42

  ▼ 6.62%
  Market cap $252.87MP/E —
  $10.73$35
• FENC

  Fennec Pharmaceuticals Inc. Common Stock

  $12.19

  ▲ 3.57%
  Market cap $334.56MP/E —
  $5.65$13.25

P/E shows — for peers not currently carrying a live signal of their own.

• Alexandra Kropotova · June 25, 2026 · Tax Withholding

  988
• Alexandra Kropotova · March 24, 2026 · Tax Withholding

  988

Institutional Ownership

March 31, 2026

Total shares held

68.41M

Total value held

$261.81M

Institutional holders

75